Fatty acid synthase (FAS) is a key enzyme in the synthesis of endogenous fatty acids. It consists of two identical polypeptide chains connected in a head-to-tail manner to form a dimer, which constitutes the catalytic center of the enzyme. It is composed of seven enzymatic active domains, and catalyzes the synthesis of fatty acids by acetyl-CoA and malonyl-CoA. The main product of FAS is palmitic acid, which is not only one of the main components of the cell membrane structure, but also an important substrate for cell energy metabolism. It stores energy, synthesizes phospholipids, and participates in cell membrane structure, intracellular signal transduction and protein acylation and many other functions. In normal tissue cells, FAS is expressed at low activity, while FAS is highly expressed in many tumor tissue cells. The level of FAS activity in vivo is of great significance to fatty acid synthesis and body fat deposition. The application of FAS inhibitors can eliminate the proliferation and migration of tumor cells and become a new therapeutic target. In recent years, scholars at home and abroad have carried out a lot of research on FAS on fat synthesis, metabolic regulation and tumor tissue. This article reviews the structure, function, origin and distribution of FAS, as well as the research progress in digestive tract tumors, correctly understands the biological characteristics of FAS and its mechanism of action in tumors, and studies new FAS inhibitors, so as to provide insights into the digestive tract. The diagnosis of tumor provides a theoretical basis and new ideas for the successful prevention and treatment of tumors.
Published in | Science Journal of Public Health (Volume 10, Issue 5) |
DOI | 10.11648/j.sjph.20221005.13 |
Page(s) | 214-222 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2022. Published by Science Publishing Group |
Fatty Acid Synthesis, Biological Characteristics, Gastrointestinal Cancer
[1] | Menendez JA. Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic require-ments of cancer cell growth: molecular mechanisms and therapeutic perspectives [J]. BiochimBiophyActa. 2010, 1801 (3): 381-391. |
[2] | Chen XH, LiCF. Research Progress in Correlation between Blood Lipid Level and Cancer [J]. Med Reca, 2018, 24 (18): 3608-3612. |
[3] | Qin F, Wang XB, Gong JP. Regulatory Mechanism of Fatty Acid Synthase Expression in Carcinogeneszs [J]. J Med Mol Biol. 2010, 7 (5): 453-456. |
[4] | Luo JX, Li CF, Chu XH, et al. Research on the Fatty Acid Synthase (FAS) Gene [J]. Chin animal husbandry and veterinary medicine. 2011, 38 (6): 118-122. |
[5] | Lan Y, Zhang Z. Advances in the study of Fatty acid synthesis enzymes in tumor cells [J]. Chin J Gero, 2015, 35 (11): 3161-3164.3164. |
[6] | Lu Z, Yang HJ, Shi K. Fatty acid synthesis, regulation of gene expression [J]. Sichuan J Anato, 2009, 17 (2): 31-35. |
[7] | Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis [J]. Nat Rev Cancer, 2007, 7 (10): 763-777. |
[8] | Maier T, Leibundgut M, Ban N. The crystal structure of a mammalian fatty acid synthase [J]. Science, 2008, 321 (5894): 1315-1322. |
[9] | Wu YX, ZhangXZ, YuJJ, et al. Effect of silencing fatty acid synthase gene (FASN) by siRNA interference on proliferation of human esophageal cancer cells [J]. J Clin Med Prac, 2013, 17 (19): 7-10. |
[10] | Hou JZ, Zhang JS, Hou ZJ. Research Development of Integrin-Linked Kinase in Gastrointestinal Tumors [J]. Med Reca, 2019, 25 (22): 4444-4448. |
[11] | ZhoU YR. Epidemic Trend and Control for Cancer Mortality [J]. Chin Canc, 2011, 20 (4): 256-258. |
[12] | Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011, 61 (2): 69-90. |
[13] | Kawada K. Diagnosis of early gastric cancer using transnasal endoscope [J]. Nihon Rinsho, 2012, 70 (10): 1748-1751. |
[14] | Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin 2021, 71: 209-249. |
[15] | Liu YY, Wei JL, Jiang R, et al. Research progresson on the epidemiology and screening of esophageal cancer [J]. Chin J Dis Control Prev, 2022, 26 (7): 839-844. |
[16] | Nemoto T, Terashima S, Kogure M, et al. Over expression of fatty acid synthase in oesophageal squamous cell dysplasia and carcinoma [J]. Pathobiology 2001, 69 (6): 297-303. |
[17] | Yuan Z, Zheng J, Hu HH, et al. Expression and clinical significance of Fatty acid synthesis in esophageal carcinoma [J]. Clin Med J China, 2005, 3 (4): 148-150. |
[18] | Ishimura N, Amano Y, Sanchez-Siles AA, et al. Fatty acid synthase expression in Barrett’s esophagus: implications for carcinogenesis [J]. J Clin Gastroenterol, 2011, 45 (8): 665-672. |
[19] | Zhou YL, Niu CY, Gao BH, et al. Expression of FAS in esophageal cancer and its effects on proliferation of TE13 cells [J]. J Shanxi Med Univ, 2014, 45 (2): 98-100. |
[20] | Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66 (2): 115-132. |
[21] | Zuo TT, Zheng RS, Zeng HM, et al. Epidemiology of stomach cancer in China [J]. Chin J ClinOnco, 2017, 44 (1): 52-58. |
[22] | Kusakabe T, Nashimoto A, Honma K, et al. Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach [J]. Histopathology, 2002, 40 (1): 71-79. |
[23] | Ito T, Sato K, Maekawa H, et al. Elevated levels of serum fatty acid synthase in patients with gastric carcinoma [J]. Oncol Lett, 2014, 7 (3): 616-620. |
[24] | Lin J, Dai HF. Diagnostic significance of levels of serum fatty acid synthase in patients with gastric carcinoma [J]. J Dalian Med Univ, 2014, (5): 475-477. |
[25] | Hu LY, Dai SC. Application value of combined detection of PG and FAS in diagnosis of gastric cancer [J]. Int J Lab Med, 2015, (8): 1092-1093. |
[26] | LI X. Diagnostic value of serum PG, MG7-Ag, TK1, FAS in gastric cancer [D].2016 master's degree thesis, Chengdu UnivTradi Chin Med. |
[27] | Duan J, Sun L, Huang H, et al. Over expression of fatty acid synthase predicts a poor prognosis for human gastric cancer [J]. Mol Med Rep, 2016, 13 (4): 3027-3035. |
[28] | Stewart BW, Wild CP. World cancer report 2014. World health organization [M]. 3rd edn. New York: International Agency for Research on Cancer (IARC) Press, 2014: Chapter 1.1. |
[29] | Xu X, Zhou J, Yang Y, et al. Expression of FAS in hepatocellular carcinoma and the effects of FAS on proliferation [J]. J Shanxi Med. 2011, 40 (10): 1275-1298. |
[30] | Liu YG, Huang JY, Yang Q, et al. Serum levels of fatty acid synthase in hepatocellular carcinoma patients and its clinical significance [J] Mod Onco, 2020, 28 (21): 3753-3755. |
[31] | Hao QW, Li T, Zhang X, et al. Expression of fatty acid synthase and its effects on the biological characteristics of hepatocellular carcinoma [J]. Chin J Exp Surg 2014, 31 (10) 2101-2104. |
[32] | Qi WH, Tao L, XiongZ, et al. Expression and roles of fatty acid synthase in hepato-cellularcarcinoma [J]. Oncology Reports, 2014 (32): 2471-2476. |
[33] | Lei Li, Giulia M P, Xiaolei Li, et al. Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans [J]. J Hepatol, 2016, 64 (2): 333-341. |
[34] | Che L, Chi W, Qiao Y, et al. Cholesterol biosynthesis supports the growth of hepato-carcinoma lesions depleted of fatty acid synthase in mice and humans [J]. Gut, 2020, 69 (1): 177-186. |
[35] | Zeng Q, Chen LY, Li GP, et al. Analysis of FOXC1 Expression and Significance in Pancreatic Dactal Adenocarcinoma Based on Bioinformatic Data [J]. Acta Med Univ Sci Techno lHua zhong, 2022, 51 (3): 309-316, 346. |
[36] | Cai J, Chen HD, Lu M, et al. Trend analysis on morbidity and mortality of pancreatic cancer in China, 2005-2015 [J]. Chinese Journal of Epidemiology, 2021, 42 (5), 794-800. |
[37] | Feng CC, Peng QL, Jiao XY, et al. Trends of Pancreatic Cancer Incidence and Mortality in China from 1990 to 2019 [J]. China Cancer, 2022, 31 (5): 321-326. |
[38] | Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors [J]. World J Oncol, 2019, 10 (1): 10-27. |
[39] | ZhU XY, Bai JH. The influence of silencing ILK gene on the proliferation of pancreatic cancer cells [J]. Prog Anat Scie, 2018, 24 (3): 250-253. |
[40] | Walter K, Hong SM, Nyhan S, et al. Serum fatty acid synthase as a marker of pancreatic neoplasia [J]. Cancer Epidemiol Biomarkers Prev, 2009, 18 (9): 2380-2385. |
[41] | Swierczynski J, Hebanowska A, Sledzinski T. Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer [J]. World J Gastroenterol, 2014, 20 (9): 2279-303. |
[42] | Bian Y, Yu Y, Wang SS, et al. Up-regulation of fatty acid synthase induced by EGFR/ERK activetion promotes tumor growth in pancreatic cancer [J]. Biochem Biophys Res Commun, 2015, 463 (4): 612-617. |
[43] | Miao CQ, Xu J, Wang J, et al. The Effect of FASN on apoptosis in pancreatic cancer [J]. J Xi-an Jiao tong Univ (Med Scie), 2015, 36 (6): 70-774. |
[44] | Huang ZW, Xue MJ, Hu YD, et al. Analysis and model prediction of disease burden attributable to various risk factors for colorectal cancer in China from 1990 to 2019 [J]. Chin J Dis Control Prev, 2022, 26 (1): 7-13. |
[45] | Zheng JJ, Mao YD, Wang CL, et al microRNA expression profile in colon cancer [J]. ActaUniv Med Anhui, 2019, 54 (3): 348-353. |
[46] | Yang ZR, Liu C, Ding LM, et al. Expression and clinical significance of Dickkopf-3 in microvessels and tumor cells of colon cancer [J]. Chin Lab Diagn, 2019, 23 (3): 387-390. |
[47] | Rashid A, Pizer ES, Moga M, et al. Elevated Expression of Fatty Acid Synthase and Fatty Acid Synthetic Activity in Colorectal Neoplasia [J]. Am J Pathol, 1997, 150. 201-208. |
[48] | Notarnicola M, Tutino V, Calvani M, et al. Serum Levels of Fatty Acid Synthase in Colorectal Cancer Patients Are Associated with Tumor Stage [J]. J Gastrointest Canc, 2012, 43: 508-511. |
[49] | Lv CT, Han L, Jiang Y, et al. Serum levels of fatty acid synthase in colorectal cancer patients and its clinical significance [J]. China Onco, 2014, 24 (8): 622-625. |
[50] | Long QQ, Yi YX, Qiu J, et al. Fatty acid synthase (FASN) levels in serum of colorectal cancer patients: correlation with clinical outcomes [J]. Tumor Biol, (2014) 35: 3855–3859. |
[51] | Zaytseva YY, Rychahou PG, Gulhati P, et al. Inhibition of Fatty Acid Synthase Attenuates CD44-Associated Signaling and Reduces Metastasis in Colorectal Cancer [J]. Cancer Res, 2012, 72 (6): 1504-1517. |
[52] | Ogino S, Ogino S, Nosho K, Meyerhardt JA, et al. Cohort Study of Fatty Acid Synthase Expression and Patient Survival in Colon Cancer [J]. ClinOncol, 2008, 26 (35): 5713-5720. |
[53] | Crispino P, Alò PL, Rivera M, et al. Evaluation of fatty acid synthase expression in oesophageal mucosa of patients with oesophagitis, Barrett’s oesophagus and adenocarcinoma [J]. J Cancer Res ClinOncol, 2009, 135 (11): 1533-1541. |
[54] | Kuchiba A, Morikawa T, Yamauchi M, et al. Body Mass Index and Risk of Colorectal Cancer According to Fatty Acid Synthase Expression in the Nurses’ Health Study [J]. J Natl Cancer Inst, 2012, 104 (5): 1-6. |
[55] | Wang HY, Xi QL, Wu GH. Fatty acid synthase regulates invasion and metastasis of colorectal cancer via Wnt signaling pathway [J]. Canc Med, 2016, 5 (7): 1599-1606. |
[56] | Lee KH, Lee MS, Cha EY, et al. Inhibitory effect of emodin on fatty acid synthase, colon cancer proliferation and apoptosis [J]. Mol Med Rep, 2017, 15 (4): 2163-2173. |
APA Style
Hou Jianzhang, Zhang Shuli, Yuan Jianlei, Li Hongyan, Hou Zhenjiang. (2022). Research Progress of Fatty Acid Synthase in Digestive Tract Tumors. Science Journal of Public Health, 10(5), 214-222. https://doi.org/10.11648/j.sjph.20221005.13
ACS Style
Hou Jianzhang; Zhang Shuli; Yuan Jianlei; Li Hongyan; Hou Zhenjiang. Research Progress of Fatty Acid Synthase in Digestive Tract Tumors. Sci. J. Public Health 2022, 10(5), 214-222. doi: 10.11648/j.sjph.20221005.13
@article{10.11648/j.sjph.20221005.13, author = {Hou Jianzhang and Zhang Shuli and Yuan Jianlei and Li Hongyan and Hou Zhenjiang}, title = {Research Progress of Fatty Acid Synthase in Digestive Tract Tumors}, journal = {Science Journal of Public Health}, volume = {10}, number = {5}, pages = {214-222}, doi = {10.11648/j.sjph.20221005.13}, url = {https://doi.org/10.11648/j.sjph.20221005.13}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sjph.20221005.13}, abstract = {Fatty acid synthase (FAS) is a key enzyme in the synthesis of endogenous fatty acids. It consists of two identical polypeptide chains connected in a head-to-tail manner to form a dimer, which constitutes the catalytic center of the enzyme. It is composed of seven enzymatic active domains, and catalyzes the synthesis of fatty acids by acetyl-CoA and malonyl-CoA. The main product of FAS is palmitic acid, which is not only one of the main components of the cell membrane structure, but also an important substrate for cell energy metabolism. It stores energy, synthesizes phospholipids, and participates in cell membrane structure, intracellular signal transduction and protein acylation and many other functions. In normal tissue cells, FAS is expressed at low activity, while FAS is highly expressed in many tumor tissue cells. The level of FAS activity in vivo is of great significance to fatty acid synthesis and body fat deposition. The application of FAS inhibitors can eliminate the proliferation and migration of tumor cells and become a new therapeutic target. In recent years, scholars at home and abroad have carried out a lot of research on FAS on fat synthesis, metabolic regulation and tumor tissue. This article reviews the structure, function, origin and distribution of FAS, as well as the research progress in digestive tract tumors, correctly understands the biological characteristics of FAS and its mechanism of action in tumors, and studies new FAS inhibitors, so as to provide insights into the digestive tract. The diagnosis of tumor provides a theoretical basis and new ideas for the successful prevention and treatment of tumors.}, year = {2022} }
TY - JOUR T1 - Research Progress of Fatty Acid Synthase in Digestive Tract Tumors AU - Hou Jianzhang AU - Zhang Shuli AU - Yuan Jianlei AU - Li Hongyan AU - Hou Zhenjiang Y1 - 2022/10/11 PY - 2022 N1 - https://doi.org/10.11648/j.sjph.20221005.13 DO - 10.11648/j.sjph.20221005.13 T2 - Science Journal of Public Health JF - Science Journal of Public Health JO - Science Journal of Public Health SP - 214 EP - 222 PB - Science Publishing Group SN - 2328-7950 UR - https://doi.org/10.11648/j.sjph.20221005.13 AB - Fatty acid synthase (FAS) is a key enzyme in the synthesis of endogenous fatty acids. It consists of two identical polypeptide chains connected in a head-to-tail manner to form a dimer, which constitutes the catalytic center of the enzyme. It is composed of seven enzymatic active domains, and catalyzes the synthesis of fatty acids by acetyl-CoA and malonyl-CoA. The main product of FAS is palmitic acid, which is not only one of the main components of the cell membrane structure, but also an important substrate for cell energy metabolism. It stores energy, synthesizes phospholipids, and participates in cell membrane structure, intracellular signal transduction and protein acylation and many other functions. In normal tissue cells, FAS is expressed at low activity, while FAS is highly expressed in many tumor tissue cells. The level of FAS activity in vivo is of great significance to fatty acid synthesis and body fat deposition. The application of FAS inhibitors can eliminate the proliferation and migration of tumor cells and become a new therapeutic target. In recent years, scholars at home and abroad have carried out a lot of research on FAS on fat synthesis, metabolic regulation and tumor tissue. This article reviews the structure, function, origin and distribution of FAS, as well as the research progress in digestive tract tumors, correctly understands the biological characteristics of FAS and its mechanism of action in tumors, and studies new FAS inhibitors, so as to provide insights into the digestive tract. The diagnosis of tumor provides a theoretical basis and new ideas for the successful prevention and treatment of tumors. VL - 10 IS - 5 ER -